Virus Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Virus Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Journal of the National Cancer Institute
JNCI news brief: Cost-effectiveness of HPV vaccination in the Netherlands
July 14th, 2009
Even under favorable assumptions, including lifelong protection against 70% of all cervical cancers and no side effects, vaccination against the human papillomavirus (HPV) is not cost-effective in the Netherlands, according to a study published online July 1 in the Journal of the National Cancer Institute. Researchers conducted the study because the cost effectiveness of HPV vaccination may be limited by the low number of cervical cancer cases and deaths in the region associated with the current Dutch cervical cancer screening program. In the study, Inge M.C.M. de Kok of the Department of Public Health at Erasmus MC, University Medical Center in...
Source: Virus Weekly (2009-07-14)
|
